BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shindo Y, Hazama S, Tsunedomi R, Suzuki N, Nagano H. Novel Biomarkers for Personalized Cancer Immunotherapy. Cancers (Basel) 2019;11:E1223. [PMID: 31443339 DOI: 10.3390/cancers11091223] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Shemesh CS, Chan P, Legrand FA, Shames DS, Das Thakur M, Shi J, Bailey L, Vadhavkar S, He X, Zhang W, Bruno R. Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden. Pharmacol Res Perspect 2020;8:e00685. [PMID: 33241650 DOI: 10.1002/prp2.685] [Reference Citation Analysis]
2 Zilenaite D, Rasmusson A, Augulis R, Besusparis J, Laurinaviciene A, Plancoulaine B, Ostapenko V, Laurinavicius A. Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma. Front Oncol 2020;10:950. [PMID: 32612954 DOI: 10.3389/fonc.2020.00950] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Liu W, Wang Y, Luo J, Liu M, Luo Z. Pleiotropic Effects of Metformin on the Antitumor Efficiency of Immune Checkpoint Inhibitors. Front Immunol 2020;11:586760. [PMID: 33603734 DOI: 10.3389/fimmu.2020.586760] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Singh R. Nanotechnology based therapeutic application in cancer diagnosis and therapy. 3 Biotech 2019;9:415. [PMID: 31696020 DOI: 10.1007/s13205-019-1940-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
5 Adam T, Becker TM, Chua W, Bray V, Roberts TL. The Multiple Potential Biomarkers for Predicting Immunotherapy Response-Finding the Needle in the Haystack. Cancers (Basel) 2021;13:E277. [PMID: 33451015 DOI: 10.3390/cancers13020277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Bracci L, Fragale A, Gabriele L, Moschella F. Towards a Systems Immunology Approach to Unravel Responses to Cancer Immunotherapy. Front Immunol 2020;11:582744. [PMID: 33193392 DOI: 10.3389/fimmu.2020.582744] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lyu L, Zheng Y, Hong Y, Wang M, Deng Y, Wu Y, Xu P, Yang S, Wang S, Yao J, Zhang D, Guo Y, Lyu J, Dai Z. Comprehensive analysis of the prognostic value and immune function of chemokine-CXC receptor family members in breast cancer. Int Immunopharmacol 2020;87:106797. [PMID: 32702599 DOI: 10.1016/j.intimp.2020.106797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yu S, Wang Y, Hou J, Li W, Wang X, Xiang L, Tan D, Wang W, Jiang L, Claret FX, Jiao M, Guo H. Tumor-infiltrating immune cells in hepatocellular carcinoma: Tregs is correlated with poor overall survival.PLoS One. 2020;15:e0231003. [PMID: 32240238 DOI: 10.1371/journal.pone.0231003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
9 Olbryt M, Rajczykowski M, Widłak W. Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors. Int J Mol Sci 2020;21:E4071. [PMID: 32517213 DOI: 10.3390/ijms21114071] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
10 Eiger D, Brandão M, de Azambuja E. Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer. ESMO Open 2020;5:e000688. [PMID: 32188717 DOI: 10.1136/esmoopen-2020-000688] [Reference Citation Analysis]
11 Deepak KGK, Vempati R, Nagaraju GP, Dasari VR, S N, Rao DN, Malla RR. Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol Res. 2020;153:104683. [PMID: 32050092 DOI: 10.1016/j.phrs.2020.104683] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 15.5] [Reference Citation Analysis]
12 Sharma VR, Singh M, Kumar V, Yadav M, Sehrawat N, Sharma DK, Sharma AK. Microbiome dysbiosis in cancer: Exploring therapeutic strategies to counter the disease. Semin Cancer Biol 2021;70:61-70. [PMID: 32693015 DOI: 10.1016/j.semcancer.2020.07.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Dey S, Trau M, Koo KM. Surface-Enhanced Raman Spectroscopy for Cancer Immunotherapy Applications: Opportunities, Challenges, and Current Progress in Nanomaterial Strategies. Nanomaterials (Basel) 2020;10:E1145. [PMID: 32545182 DOI: 10.3390/nano10061145] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
14 Nie X, Song L, Li X, Wang Y, Qu B. Prognostic signature of ovarian cancer based on 14 tumor microenvironment-related genes. Medicine (Baltimore) 2021;100:e26574. [PMID: 34260536 DOI: 10.1097/MD.0000000000026574] [Reference Citation Analysis]
15 Zhou Z, Song Q, Yang Y, Wang L, Wu Z. Comprehensive Landscape of RRM2 with Immune Infiltration in Pan-Cancer. Cancers (Basel) 2022;14:2938. [PMID: 35740608 DOI: 10.3390/cancers14122938] [Reference Citation Analysis]
16 Coskun A, Sandberg S, Unsal I, Serteser M, Aarsand AK. Personalized reference intervals: from theory to practice. Crit Rev Clin Lab Sci 2022;:1-16. [PMID: 35579539 DOI: 10.1080/10408363.2022.2070905] [Reference Citation Analysis]
17 Krug K, Jaehnig EJ, Satpathy S, Blumenberg L, Karpova A, Anurag M, Miles G, Mertins P, Geffen Y, Tang LC, Heiman DI, Cao S, Maruvka YE, Lei JT, Huang C, Kothadia RB, Colaprico A, Birger C, Wang J, Dou Y, Wen B, Shi Z, Liao Y, Wiznerowicz M, Wyczalkowski MA, Chen XS, Kennedy JJ, Paulovich AG, Thiagarajan M, Kinsinger CR, Hiltke T, Boja ES, Mesri M, Robles AI, Rodriguez H, Westbrook TF, Ding L, Getz G, Clauser KR, Fenyö D, Ruggles KV, Zhang B, Mani DR, Carr SA, Ellis MJ, Gillette MA; Clinical Proteomic Tumor Analysis Consortium. Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell 2020;183:1436-1456.e31. [PMID: 33212010 DOI: 10.1016/j.cell.2020.10.036] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 14.5] [Reference Citation Analysis]
18 Novak D, Utikal J. New Biomarkers in Cancers. Cancers (Basel) 2021;13:708. [PMID: 33572354 DOI: 10.3390/cancers13040708] [Reference Citation Analysis]
19 Andreatos N, Iyer G, Grivas P. Emerging biomarkers in urothelial carcinoma: Challenges and opportunities. Cancer Treat Res Commun 2020;25:100179. [PMID: 32920502 DOI: 10.1016/j.ctarc.2020.100179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
20 Watson GA, Doi J, Hansen AR, Spreafico A. Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift? Br J Clin Pharmacol 2020;86:1753-68. [PMID: 32394468 DOI: 10.1111/bcp.14355] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Evangelista L. The prediction of response to immunotherapy in non-small cell lung cancer patients by 18F-FDG PET/CT. J Thorac Dis 2019;11:E221-3. [PMID: 31903287 DOI: 10.21037/jtd.2019.10.19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]